TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that Dror Harats, M.D., chief executive officer of VBL, is scheduled to present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at 12:00 p.m. EDT at the Grand Hyatt New York.
